How COVID-19 Has Changed the Management of Glomerular Diseases.
暂无分享,去创建一个
[1] S. Mohan. Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York. , 2020, Journal of the American Society of Nephrology : JASN.
[2] Marc A Pfeffer,et al. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.
[3] L. Tomlinson,et al. Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. , 2020, Clinical journal of the American Society of Nephrology : CJASN.
[4] D. Batlle,et al. Renin-Angiotensin System Blockers and the COVID-19 Pandemic , 2020, Hypertension.
[5] A. Levin,et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. , 2020, The New England journal of medicine.
[6] B. Rovin,et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. , 2019, The New England journal of medicine.
[7] J. Lieske,et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. , 2019, Kidney international.
[8] David W. Johnson,et al. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial , 2017, JAMA.
[9] F. Schena,et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. , 2015, The New England journal of medicine.
[10] F. Eitner,et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. , 2016, The New England journal of medicine.